Innovent Biologics has received China’s National Medical Products Administration (NMPA) approval for the New Drug Application ...

AstraZeneca and Daiichi Sankyo’s Enhertu's breakthrough therapy designation as a post-neoadjuvant treatment option for ...

Liquid biopsy using ctDNA refines risk stratification for patients with residual cancer burden post-neoadjuvant therapy, aiding in treatment decisions. ctDNA-negative status in resistant tumors ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

In a propensity score-matched analysis, adjuvant therapy was significantly associated with a higher risk for all-cause and cancer-specific mortality and disease recurrence compared with neoadjuvant ...

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

Hello. It's Mark Kris from Memorial Sloan Kettering. Recently, I presented information about the published trials of neoadjuvant nivolumab chemotherapy vs chemotherapy, showing robust, disease-free ...

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

In this study, researchers aimed to determine whether Ki67 and TILs in residual breast tumors were prognostic for survival in patients with triple-negative breast cancer who received neoadjuvant ...

ENHERTU® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer ...